BioNTech SE will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech’s clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches. Highlights of BioNTech’s clinical stage programs to be presented at ESMO Congress 2024: Updates on several Phase 2 and Phase 1/2 clinical trials evaluating BNT327/PM8002 in various indications as monotherapy and in combination with chemotherapy will be presented; Preliminary data from an ongoing clinical Phase 2 trial evaluating BNT113 in combination with PD-1 blockade and data from an investigator-initiated Phase 1/2 clinical trial ; Preliminary data of the randomized Phase 2 clinical trial with BNT316/ONC-392; Follow-up data of activity and immune responses from the ongoing first-in-human Phase 1 clinical trial.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Tempus announces real world data collaboration with BioNTech
- FDA Approves BioNTech’s Updated COVID-19 Vaccine
- Pfizer, BioNTech confirm FDA approval for updated COVID-19 vaccine
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
- Pfizer, BioNTech confirm FDA approval for update COVID-19 vaccine